Inactief instrument

Andere talen 3SBio Inc. (ADR) Nasdaq

Aandelen

US88575Y1055

slotkoers Nasdaq Andere beurzen
- ^USD	-

22/04	3Sbio Inc. Kondigt wijzigingen in het management aan	CI
12/04	3SBio Inc. Keurt Recombinant Humane Trombopoëtine Injectie (TPIAO) goed voor Pediatrische ITP-indicatie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

3Sbio Inc. Announces Management Changes	22/04
3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia	15/04
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication	12/04
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023.	27/03
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates	21/03
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024	20/03
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product	08/01
Mandi Foam of 3SBio Inc. Approves for Market Launch	08/01
Venus Medtech Names Former 3SBio Finance Chief as CFO	04/01
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China	02/11
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates	25-08-23
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced	25-08-23
3SBio : 2023 Interim Results Presentation	24-08-23
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	24-08-23
3SBio Hires Former JPMorgan Exec as CFO	31-07-23
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer	28-07-23
3SBio Rolls Out Pruritus Medication in China	06-07-23
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market	05-07-23
3SBio Inc.'s Equity Buyback announced on July 15, 2022, has expired.	20-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen 3SBio Inc. (ADR) Nasdaq

Aandelen

US88575Y1055

Andere talen

Filters